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Abstract 
1 Abstract 
Introduction 
Renal Fanconi syndrome describes a general dysfunction of the proximal tubules 
characterised by urinary losses of water, electrolytes, low-molecular weight 
proteins, amino acids and glucose. The heterogeneity of its underlying causes 
has complicated the understanding of renal Fanconi syndrome for many years. 
Recent studies of its isolated form, only affecting the proximal tubule and no 
other nephron segments, allow new insights into the understanding of 
pathophysiology and development of disease models.  
Areas Covered 
In this review, we discuss the most recent insights into pathophysiology of renal 
Fanconi syndrome as well as novel disease and potential developments of new 
therapeutic strategies.  
Expert Opinion 
The importance of fatty acid oxidation in proximal tubules has just recently been 
established. So far this has not yet led to pharmaceutical development of 
medicines, due to lack of understanding of the exclusive use of fatty acids by 
mitochondria in the proximal tubule for energy generation. Nevertheless, novel 
insights have resulted in potential targets for development of new therapeutic 
strategies, including mir21 and mTORC1. 
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2 Introduction 
Renal Fanconi Syndrome (RFS) is a generalised dysfunction of the first post-
glomerular segment, the proximal renal tubule, leading to excessive urinary loss of 
fluid and solutes. It is named after Guido Fanconi, a Swiss paediatrician who was 
among the first describing this syndrome in the early 1930s [1] in parallel with De 
Toni and Debre [2, 3]. RFS might cause massive and life-threatening losses of free 
water, bicarbonate, sodium chloride and potassium, as well as losses of other freely 
filtered substances such as phosphate, amino-acids, uric acid, low-molecular-weight 
(LMW) nutrients and glucose. Many of these valuable solutes can be reabsorbed 
along the kidney only through the highly specialized proximal tubule epithelial cells 
[4]. Children might present with failure to thrive, polyuria, polydipsia, dehydration, 
and rickets, whereas adults might develop osteoporosis and osteomalacia. Clinical 
features also include renal salt wasting, hypokalaemia, metabolic acidosis and LMW 
proteinuria [5]. In adults, the renal glomeruli produce more than 150 litres of 
ultrafiltrate every day, containing approximately 20 mol of sodium (the equivalent of 
more than 1 kg of salt) and >150 g of sugar [6, 7]. Normally, approximately 70% of 
filtered salt and water and virtually all of filtered sugars, amino acids and proteins are 
reabsorbed along the proximal tubule [4]. Thus, with complete loss of PT function, up 
to 120 L of water and solutes, would be lost per day, indicating the importance of PT 
function. Complete loss of function is probably not compatible with life and to a 
degree other nephron segments can compensate, but it is the overspill of water and 
solutes into the urine that defines the RFS phenotype.  
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3 Maintaining proximal tubule homeostasis 
The enormous reabsorptive capacity is provided by a whole orchestra of specialized 
apical, basolateral and paracellular transporters driven by the electrochemical 
gradient generated by the basolateral Na+-K+-ATPase (see figure 1). To optimise 
the reabsorption, cell and transport properties change along the PT. We distinguish 
three sub-segments, S1-S2-S3, each one lined with different cell types. Moreover, 
PT cells (mainly S1-S2), express large multiligand endocytic receptors, namely, 
megalin, cubilin and, perhaps, amnionless that mediate the uptake of the freely 
filtered LMW proteins [8]. In order to increase the available apical surface area, 
those PT cells are decorat d with differentiated brush borders. The paracellular 
spaces have a highly dynamic membrane structure: tight junctions, adherens 
junctions and gap junctions, which play a vital role in epithelial barrier function. 
Claudin-2 is the main protein responsible for the selective paracellular transport 
pathway for various ions (mainly sodium) and water [9, 10].  
3.1 Proximal tubule controlling the Acid –base balance  
Tight regulation of the extracellular H+ concentration is essential for almost all 
enzyme activity, as alteration in charge might disrupt their function [11]. About 80% 
of the filtered HCO3- (which is the major buffer in the extracellular fluid) is indirectly 
reabsorbed by the PT cells. Bicarbonate reabsorption relays on a complicated 
sequence of events which start at the apical side by active secretion of hydrogen ion 
through Na+/H+ (isoform 3, NHE3) antiporter, using the electrochemical gradient for 
sodium uptake into the cell as driving force, which is maintained by the basolateral 
Na+/K+ ATPase [7, 12]. In this way, sodium and thus volume homeostasis is 
molecularly coupled to acid-base homeostasis. The secreted hydrogen ion combines 
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with filtered bicarbonate and is the resultant carbonic acid is converted by carbonic 
anhydrase IV into water and carbon dioxide. The latter diffuses into the proximal 
tubular cells via aquaporin 1 [13], where hydroxylation occurs to form bicarbonate in 
the presence of intra-cellular carbonic anhydrase II. Intracellular HCO3- is co-
transported with Na+ at the basolateral membrane via kNBCe1-A in a 1:3 ratio.  
Interestingly, plasma CO2 and HCO3
- at the basolateral membrane appear to be 
critical for regulation of bicarbonate reabsorption rather than plasma pH [13]. 
3.2 Proximal tubule controlling water and salt balance  
Alterations in sodium balance maintain intravascular volume rather than sodium 
concentration. Regulation of plasma volume occurs as a response to renal perfusion, 
as the kidney cannot sense serum sodium. Approximately 60-70% of the filtered 
NaCl is reabsorbed by the PT, which therefore plays a critical role in the regulation of 
plasma volume and blood pressure. The basolateral 2K+/3Na+ ATPase pump is 
crucial in generating the electrochemical driving force with low intracellular sodium 
concentration, high intracellular potassium concentration, which via potassium 
channels establish a negative intracellular potential difference across the apical and 
basolateral membranes. The sodium gradient and the intra-cellular electronegativity 
are the driving force for sodium reabsorption along the apical membrane of the PT. 
This electrochemical driving force for sodium uptake is utilised for multiple transport 
processes, such as coupled transport (sodium co-transport with glucose, phosphate, 
or amino-acids), exchange (Na+/H+ exchanger type 3 NHE3), and passive diffusion 
via channels [14]. Water is reabsorbed along with these solutes, as the proximal 
tubule is fully water permeable due to the constitutive expression of aquaporin 1 
water channels. Consequently, the urinary fluid leaving the proximal tubule has the 
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same tonicity as the initial glomerular filtrate as solute reabsorption occurs 
isotonically [5]. In patients with RFS there is impaired reabsorption o f  sodium and 
other solutes, as well as water in the proximal tubules leading to hypotension and 
dehydration. Increased delivery of sodium to the distal tubules, as well as the 
hypovolaemia, activates renin-angiotensin system, which leads to potassium wasting 
in the distal tubules and to clinical hypokalaemia as a consequence.  
3.3 Proximal tubule controlling phosphate reabsorption  
Under physiological conditions, around 80% of the freely filtered phosphate (Pi) is 
reabsorbed along the proximal tubules mainly along the convoluted segment. The 
involved Pi transporters (mainly NaPi IIa, NaPi IIc) are secondary-active sodium 
phosphate co-transporters, confined to the apical brush border membrane. Tubular 
Pi reabsorption is controlled by a number of hormones (parathyroid hormone, 1,25-
dihydroxyvitamin D3, FGF-23, glucocorticoids) and metabolic factors (phosphate 
loading, metabolic acidosis), by changing the apical expression of Na+/Pi co-
transporters at the brush border membrane [15, 16].  
Most of the patients with RFS present with low tubular reabsorption of phosphate 
(<80–85%) and decreased serum phosphate. Of note, with very low plasma 
phosphate levels, the reabsorptive capacity of the PT may keep up reabsorption with 
this decreased filtered phosphate load, so that TRP can be normal in RFS. For this, 
reason, the TmP/GFR (= SP-UP x SCr:UCr) is a better tool to assess renal 
phosphate handling [17]. Rickets in children and osteomalacia in adult are 
secondary to the increased urinary wasting of phosphate and impaired 1-alfa 
hydroxylation of vitamin D (see below).  
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3.4 Proximal tubule controlling LMW protein reabsorption 
The glomeruli filter significant amounts of protein into the primary human urine, yet 
the finally excreted urine is almost entirely protein-free. The glomerular filtration 
membrane retains proteins larger than about 60 kDa, with some exceptions, such as 
albumin (66 kDa) and transferrin (81 kDa), which pass through to some extent [18]. 
In the kidney, the proximal tubule is the only nephron segment involved in the 
reabsorption of LMW proteins. The renal proximal tubule reabsorbs almost the entire 
physiologically filtered protein load, including albumin and LMW proteins. LMW 
proteins and albumin are reabsorbed via a luminal receptor mechanism. The active 
processes by which the renal proximal tubule reabsorbs filtered plasma proteins, 
vitamins, vitamin-binding proteins, and hormones are vital for body homeostasis and 
take place mainly in the first two segments of the proximal tubule [8]. The apical 
cubilin-megalin complex plays an essential role in this process [19]. The three 
promiscuous receptors, megalin, cubilin and amnionless, cooperate in the proximal 
tubule in order to reabsorb nearly all filtered plasma protein. They work in concert 
notwithstanding their considerable structural differences. In RFS, proteinuria, which 
can be within the nephrotic range, is predominantly caused by the dysfunction of 
protein reabsorption in the proximal tubules [20].  
 
Proximal tubule and vitamin D metabolism 
Vitamin D, a lipid, is mostly bound to a specific carrier protein in plasma, vitamin D 
binding protein (VDBG). VDBG is a LMW protein, that is filtered by the glomerulus 
and then reabsorbed in the proximal tubules via megalin. In this way it becomes 
available for the critical activation step of 1-alfa hydroxylation, which occurs in the PT 
mitochondria.  
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4 Disease model 
4.1 Part of multisystem metabolic diseases causing accumulation of toxic 
metabolites 
4.1.1 Cystinosis 
Cystinosis is an autosomal recessive lysosomal storage disorder caused by 
mutations in the CTNS gene coding for the lysosomal cystine/proton transporter 
cystinosin. It is characterized by the accumulation of cystine in all organs, mainly 
kidney, cornea, bone marrow, thyroid, lymph nodes, liver and spleen [21] . It is the 
most common cause of inherited RFS in children with an estimated incidence of 0.5-
1.0 per 100 000 live births [22]. There are three main clinical forms described 
depending on the age of onset and severity of disease: Infantile, juvenile or adult 
form [23]. The infantile (nephropathic) form is the most severe and most common 
(95%) form leading to symptoms of renal RFS during the first year of life. Patients 
may also develop severe rickets and growth retardation due to phosphaturia. At 
onset patients usually have normal kidney function, but progress to end stage kidney 
disease (ESKD) around the age of 10 years if no adequate treatment is provided. 
The juvenile (nephropathic) form and the adult (non-nephropathic) form are less 
severe and less common. Patients with the juvenile form present with milder forms of 
RFS with later progression to renal failure, whereas the adult form is characterized 
by isolated corneal cystine crystal deposition [24]. 
Pathophysiology 
Current evidence shows that cystinosis is a monogenic-recessive disease with 
complete penetrance. The underlying bi-allelic mutations are located in the CTNS 
gene encoding the lysosomal cystine transporter cystinosin. The gene consists of 12 
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exons and the most common mutation (>70% in Caucasians) is a 57kb deletion, 
which includes the first nine exons and a part of exon 10 of the CTNS gene [1, 25]. 
The mutation also involves the adjacent CARKL gene and the first two non-coding 
exons of the TRPV1 gene. However, no clinical correlation has been reported so far 
with the CARKL and TRPV1 genes in affected patients [26], except for perhaps an 
increased tolerance to spicy food. More than 100 mutations in the CTNS gene are 
described with novel mutations still being reported [27, 28]. The differences of the 
clinical phenotype in the different forms are explained by more severe mutations in 
both alleles in the infantile cystinosis versus milder mutations in the juvenile and 
adult form.  
The CTNS gene codes for cystinosin, which is a 367 amino acid protein with seven 
transmembrane domains . It functions as a proton/cystine co-transporter and is 
driven by the high proton content within the lysosomal lumen. A defect in the 
transport mechanisms causes accumulation of cystine in the lysosomal lumen with 
formation of cystine crystals and cell atrophy [29]. The mechanistic links between 
lysosomal cystine accumulation and the development of RFS have been studied in 
several in vitro studies but still remain not fully understood [30]. A recent Ctns-/- mice 
study provided some insight into the pathophysiology by showing that lysosomal 
cystine inclusion leads to apical proximal tubular cell (PTC) dedifferentiation with 
reduced expression of multi-ligand megalin and cubilin receptor and NaPi-IIa, 
followed by PTC atrophy [31]. It has been shown that lesions start developing in 
segments adjacent to the glomerulotubular junction and then extend longitudinally 
along the proximal tubulus. This explains proximal tubular cell flattening, also 
referred as “swan neck lesions”, the typical finding seen in biopsies from cystinotic 
children [32, 33].  
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Clinical presentation and diagnosis 
Clinical symptoms of RFS in the infantile form are heterogeneous. Affected children 
generally present early and manifest symptoms at the age of 6-12 months. 
Presenting symptoms are polyuria, polydipsia, dehydration, fluid and electrolyte loss, 
aminoaciduria, glucosuria, proteinuria, failure to thrive and/or rickets. Development of 
ESKD depends on the age of treatment initiation [34]. Diagnosis is usually confirmed 
by elevated cystine levels in peripheral leukocytes along with corneal cystine crystals 
demonstrated by the split lamp exam and consecutive genetic analysis of the CTNS 
gene. 
Treatment 
Fluid and electrolyte management is the main supportive therapy in patients with 
Fanconi syndrome secondary to cystinosis. Additionally, the supplement of oral 
cysteamine, a cystine-depleting agent, is crucial in the treatment for cystinosis [35-
39]. Early initiation of cysteamine treatment has been proven to delay the progress of 
ESKD and should be provided to every patient with the diagnosis of cystinosis. A 
new treatment target, transcription factor EB (TFEB) has been suggested recently. 
TFEB activates the transcription of different proteins involved in the cell clearance 
and has been shown to promote clearance of cystine storage in cells within 24 hrs 
and might also lead to a rescue of the lysosomal compartment of cells affected by 
cystinosis [40]. 
 
4.1.2 Fanconi–Bickel syndrome 
Pathophysiology  
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Fanconi-Bickel syndrome (FBS) is an autosomal recessive disease of carbohydrate 
metabolism caused by mutations of the GLUT2 gene (also referred as SLC2A2) 
coding for a glucose transporter in hepatocytes, pancreatic beta-cells, enteral cells 
and renal tubular cells [41]. Over 34 different mutations have been reported. These 
mutations included missense, nonsense, frameshift and splice-site mutations, 
scattered over the whole coding sequence of SLC2A2 gene and with none of those 
mutations being particularly frequent [41, 42]. 
Clinical presentation  
FBS is characterized by hepatomegaly and nephromegaly caused by glycogen 
accumulation. Further, impaired utilization of glucose and galactose leads to fasting 
hypoglycemia and postprandial hyperglycemia, combined with galactose intolerance 
and development of Fanconi syndrome, rickets and severe short stature [43]. 
Treatment 
Therapy is mainly supportive and focuses on maintaining glucose homoeostasis, 
with frequent feeding including night-time. Moreover, treatment should aim to 
compensation of renal solute losses including sodium bicarbonate, potassium and 
phosphate supplements.  
 
4.1.3 Tyrosinemia type I  
Pathophysiology  
Tyrosinemia type 1 is an autosomal recessive disease of the amino acid metabolism 
caused by a mutation in the fumarylacetoacetate hydrolase (FAH) gene coding for 
the last enzyme in the tyrosine catabolic pathway, which catabolizes the conversion 
of fumarylacetoacetate (FAA) into fumarate and acetoacete. FAH is mainly 
expressed in the liver and kidney, where lack of FAH causes accumulation of toxic 
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metabolites such as maleylacetoacetate (MAA) and fumarylacetoacetate (FAA) and 
their derivates succinylacetone, leading to progressive liver disease and RFS [44]. 
The accumulation of those metabolites disrupt the sulfhydryl metabolism by forming 
glutathione adducts which makes cells more vulnerable to free radical damage. 
Further FAA and MAA are known mutagens and can promote cell apoptosis [44]. As 
a response to those intracellular effects hepatic and renal cells developing cell 
apoptosis or mutation if they are exposed to high levels of FAA or MAA. In the kidney 
that leads to glumerulosclerosis and interstitial fibrosis [45]. Symptoms include 
progressive hepatic dysfunction beginning in early childhood with progression to 
cirrhosis and hepatocellular carcinoma. Kidney involvement is represented by the 
development of RFS and hypophosphatemic rickets.  
Clinical presentation and diagnosis 
Clinical symptoms can be related to progressive liver damage with reduced 
coagulation factors, hypoglycemia and acute hepatic crisis such as ascites, 
jaundices and gastrointestinal bleeding. One third of the patients will develop liver 
cancer [46]. In regards to the renal involvement, patient show abnormal renal 
architecture (increased size and echogenicity on renal ultrasound) and development 
of tubular dysfunction including hypophosphatemic rickets with hypercalciuria, 
generalized aminoaciduria, renal tubular acidosis and mild proteinuria. Glycosuria is 
less common due to in general low blood glucose levels.  
Diagnosis includes confirming elevated levels of succinylacetone in plasma and 
urine. Plasma tyrosine and methionine levels are usually elevated in untreated 
patients.  
Treatment 
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First line treatment includes a low phenylalanine and low tyrosine diet and early 
treatment with NTBC [2-(2-nitro-4-trifluoro-methylbenzyol)-1,3-cyclohexanedione] an 
inhibitor of 4-hydroxyphenylpyruvate-dioxygenase. NTBC has been shown to prevent 
the accumulation of fumarylacetoacetate and its conversion to succinylacetone, and 
can rapidly improve tubular function in patients with Tyrosinemia type 1, leading to 
significant improvement of proteinuria and mean plasma phosphate levels [44, 47].  
 
4.1.4 MODY 1 
Recently, RFS has been described in association with MODY 1 (maturity onset 
diabetes of the young type 1) caused by a heterozygous mutation R63W (previously 
annotated as R76W) in the HNF4A gene [48]. Different mutations in the HNF4A 
gene have been described to cause neonatal hyperinsulinism followed by decreased 
insulin secretion later on in live. Why only this particular dominant mutation also 
causes RFS remains to be investigated [6]. 
 
4.1.5 Others 
Other genetic forms of RFS include Galactosemia, an autosomal recessive disease 
of the galactose metabolism caused by deficiency of galactose-1-phophate 
uridyltransferase (GALT). Patients normally present in the neonatal period after first 
intake of galactose with severe symptoms including lethargy, jaundice, liver disease, 
sepsis, cataract and RFS [49]. 
Wilsons disease, an autosomal recessive inborn error of copper metabolism 
caused by defects in the copper-transporting P-type ATPase beta-polypeptide 
(ATP7B) with reduced ceruloplasmin synthesis and biliary excretion of copper. 
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Patients develop progressive liver disease, progressive neurological disorders and 
RFS [50, 51]. 
Hereditary fructose intolerance, an autosomal recessive disorder with deficiency 
of aldolase B which catalyses the metabolism of fructose and leads to an inability to 
metabolize fructose. Patients presents with vomiting, hypoglycemia, 
hypophosphatemia, hyperuricosuria, hyperuricemia and growth retardation [51, 52]. 
4.2 Disruption of endocytosis and intracellular transport 
4.2.1 Lowe syndrome 
Oculo Cerebro Renal Syndrome of Lowe (OCRL) is an X-linked recessive 
multisystem disorder characterised by congenital cataracts, intellectual disability, and 
renal tubulopathy (OMIM 309000). Lowe syndrome results from loss-of-function 
mutations in OCRL which encodes phosphatidylinositol 4,5-bisphosphate 5-
phosphatase (PtdIns(4,5)P2 5-phosphatase) [53]. In humans, this enzyme is 
expressed primarily in the kidney, brain, and eyes, which are consequently the main 
organs affected by OCRL syndrome [54, 55]. Localisation of the OCRL enzyme to 
the endosomal apparatus suggests that it may play a role in intracellular trafficking, 
sorting, and recycling of apical membrane multi-ligand receptors megalin-cubilin [56-
58]. The precise molecular link between the OCRL enzyme and receptors on the cell 
surface remains elusive [59, 60]. Treatment is symptomatic due to absence of 
efficient therapy [61]. 
4.2.2 Dent disease 
Dent 1  
Dent disease is an X-linked recessive disease, often associated with progressive 
kidney function impairment. The first identified causative gene was CLCN5 
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(Xp11.22) (Dent 1 disease), which accounts for approximately 60% of reported 
pedigrees. CLCN5 is a chloride/proton anti-porter that works together with the 
electrogenic H+-ATPase to achieve endosomal acidification, which is a crucial step 
in normal endosomal function [62]. Loss-of-function mutations of CLCN5 result in 
hypercalciuria, nephrolithiasis, metabolic acidosis, aminoaciduria, glycosuria, 
hypophosphatemic rickets due to hyperphosphaturia, and LMW proteinuria [63]. 
Norden et al. [64] found a striking deficiency of urinary megalin protein in Dent’s 
disease patients compared with normal controls. They concluded that reduced 
shedding of megalin receptor from the apical membrane to the urine flow reflects the 
abnormal recycling of the receptor back to the apical membrane. This defect would 
interfere with the normal endocytic function of megalin, resulting in losses of potential 
ligands into the urine and leading to tubular proteinuria.  
 
Dent 2 
Investigations in families with Dent disease in whom CLCN5 mutations had been 
excluded led to the surprising discovery of mutations in OCRL, the gene previously 
identified as the cause of Lowe syndrome. Mutations in this gene account for about 
15–20% of cases of Dent’s syndrome and these are now referred to as Dent 2 
disease [54, 65]. The cause for the pleiotropy of OCRL is not fully elucidated, 
although there is some genotype-phenotype correlation in that the vast majority of 
Dent 2 mutations are located on exon 9, whereas mutations causing Lowe syndrome 
are typically located in exon 8-23 [66]. Nevertheless, there is no clear separation with 
nonsense mutations with assumed complete loss of function found in both Dent 2 
and Lowe patients. These phenotypes are now believed to be two ends of a 
phenotypic spectrum [67]. Bockenhauer et al. [56] investigated eight boys with Dent 
Page 15 of 33
URL: http://mc.manuscriptcentral.com/eood   Email: Lizzie.Howard@informa.com
Expert Opinion on Orphan Drugs
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
16 
2. All had LMW proteinuria and hypercalciuria, but none developed renal tubular 
acidosis. Hoopes et al. reported on five families with a similar phenotype [65]. 
The care of patients with Dent’s disease is supportive, focusing on the prevention of 
nephrolithiasis [63].  
 
 
4.3  Genetic renal Fanconi syndrome  
Three genetic forms of renal Fanconi syndrome have been described: Fanconi 
renotubular syndrome FRTS types 1 -3.  
4.3.1 FRTS1 
The first form has been mapped on chromosome 15, although the gene has not 
been identified yet [68]. FRTS 1 is also associated with progressive chronic kidney 
disease, but the underlying mechanism remains unknown and as such no 
therapeutics are available yet.  
4.3.2 FRTS2 - SLC34A1 
FRTS2 is caused by homozygous in-frame 21 bp duplications in SLC34A1, which 
codes for the phosphate transporter NAPi-IIa [15]. It has only been reported in few 
patients so far [15, 69]. The phenotype is dominated by phosphate wasting and 
rickets despite high 1,25 OH vitamin D levels. Interestingly not all proximal tubular 
functions are affected and renal tubular acidosis was not present in the reported 
cases. However, the underlying mutation in SLC34A3 has been described before to 
cause hereditary hypophosphatemic rickets with hypercalciuria [70]. Mutations in 
SLC34A1 are now recurrently identified in patients with infantile hypercalcaemia [71]. 
The reason for this pleiotropy is again poorly understood but for the RFS, the 
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underlying mechanism has been proposed to be intracellular phosphate depletion 
leading to insufficient ATP generation [6]. 
4.3.3 FRTS3 - EHHADH 
The third form is an isolated full blown RFS caused by heterozygous missense 
mutation in a gene called EHHADH first described by Klootwijk et al. [72]. The 
phenotype presents as isolated Fanconi syndrome with no progression to chronic 
kidney disease. An interesting aspect of this disease is the realisation that despite 
lifelong loss of water and solutes glomerular kidney function is preserved. The 
disease mechanism has been identified as a dominant negative effect from 
intracellular mistargeting of the mutated enzyme [72, 73]. Whilst the enzyme (and 
thus the mutation in patients) is expressed ubiquitously, symptoms only manifest in 
the proximal tubule. The reason for this is the dependency on fatty acid metabolism 
for energy generation in the proximal tubule [74]. EHHADH interferes with a 
mitochondrial enzyme that is involved in mitochondrial fatty acid oxidation and has a 
high degree of homology to EHHADH. So the erroneous assembly of mutant 
mislocalised EHHADH into this enzyme leads to a defect in ATP production causing 
RFS. In other tissues, glucose can be metabolised and ATP generation is thus not 
affected [6]. 
 
4.4 Acquired forms of renal Fanconi syndrome  
Multiple drugs have been described to cause tubular damage and consequently 
RFS. Those include HIV therapy, heavy metals (cadmium/lead administration), 
antibiotics, valproic acid as well as exogenous factors as glue sniffing and exposure 
to suramin, fumaric acid, or ifosfamide [75, 76]. Most of those drugs are freely 
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filtrated in the glomerulus and reabsorbed in the tubules, where they interfere with 
different parts of the proximal tubules [77]. 
Further RFS has been described in association with monoclonal gammopathies 
(adult) nephrotic syndrome, Sjörgen syndrome and others [78-81]. 
 
5 Expert opinion 
The clinical experience leading the research of the last decades has partially 
unravelled the pathogenic mechanisms leading to different forms of RFS. Thus, the 
common element involved in the heterogeneous nature of RFS, including from 
acquired to different genetic causes, with seemingly different molecular pathologies, 
is the dysfunction of a cellular organelle, mitochondria.  
The renal toxicity of some of the therapeutic agents including anti-retroviral 
therapeutics, and the anti-epileptic valproic acid [82] has been intensively discussed 
even though the pathologies for these acquired RFS forms are not completely 
deciphered [6, 82-84]. The key findings in the field of RFSs focused on identification 
of mono-genetic causes [72, 84]. A recent study about a large mono-genetic RFS 
family validated mitochondria's role by showing defective fatty acid oxidation due to a 
particular mutation (E3K) in EHHADH. Surprisingly this mutation resulted in 
mistargeted EHHADH resulting in disruptive formation of the mitochondrial 
trifunctional protein complex now encompassing the mutated EHHADH. These 
findings provide new clues for treatment of this type of renal Fanconi syndrome 
(FRTS3), and other RFS as well.  
Future therapeutic strategies could be directed in strengthening or protecting the 
mitochondria against toxic substances either through controlling the import of 
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proteins to mitochondria or through therapeutically targeting mitochondrial fatty acid 
oxidation in RFS (Figure 2). In contrast with the findings related to fatty acid 
oxidation, apoptosis has been for a long time associated with certain types of RFS 
[85].  
All these future therapeutic strategies for treatment of RFS that came to existence 
due to novel research findings in identification of the patho-mechanistic nature of 
RFSs will be discussed in the next few paragraphs.   
 
5.1. Potential Treatment options 
 
5.1.1. Targeting protein import problems in ATP deficiency related RFS 
 
FRTS3 patients have been shown to have a fatty acid accumulation problem leading 
to a decreased ATP production [72, 73]. In order to address the fatty acyl 
accumulation problem in FRTS3, the import of the causative mutated protein could 
be prevented by using the FDA approved drug Dequalinium chloride (DECA), 
recently shown to be effective in restoring mitochondrial function in a cell model for 
primary hyperoxaluria I [86]. The agent DECA holds great promise as a therapeutic 
targeting strategy in FRTS3, although there is only one FRTS3 family known to date.  
 
In other forms of RFS, where there is general mitochondrial dysfunction, achieving 
the opposite by increasing protein import may be a therapeutic option. Thus, the 
FDA-approved mitochondrial protein import stimulator sodium pyrithione has recently 
been shown to improve mitochondrial bioenergetics in Leigh patients [87]. This might 
also be relevant for acquired forms of RFS that are associated with ATP deficiency 
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and/or oxidative phosphorylation defects, e.g. aminoglycosides and valproic acid 
associated RFS. 
 
5.1.2. Anti-oxidant therapy for RFSs 
 
The use of anti-oxidants like sirtuins and SS-peptides, MitoQ, and plastoquinone 
analogues and stanniocalcin-1 have also been suggested as potential therapeutical 
agents for RFS [88].  
In addition, due to their nature of boosting the fatty acid oxidation, anti-oxidants like 
carnitine, fibrates and poly unsaturated fatty acids in form of a specific ketogenic diet 
could be investigated in the future as a potential treatment option for specific forms 
of RFS, like valproic acid induced RFS. These type of RFS have been shown to 
have inhibited fatty acid oxidation master-regulators like peroxisome proliferator-
activated receptor-alpha activity or PGC-1alpha, leading to deficient fatty acid 
oxidation [89, 90]. 
 
5.1.3 Anti-apoptotic therapy for fumaric acid ester induced RFS, Tyrosinemia 
type I and Cystinosis 
 
Mitochondrial drug targeting to prevent apoptosis from happening has the potential 
to be used in RFS forms triggered by apoptosis, such as tyrosinemia type I, 
cystinosis, light-chain proximal tubulopathy or fumaric acid ester associated RFS. To 
this end caspase inhibitors can be used A good candidate that was proven 
successfully in a mouse model for fumaric acid ester associated proximal 
tubulopathy is the anti-apoptotic caspase inhibitor YVAD [91]. Other caspase 
Page 20 of 33
URL: http://mc.manuscriptcentral.com/eood   Email: Lizzie.Howard@informa.com
Expert Opinion on Orphan Drugs
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
21 
inhibitors with clinically approved status that could potentially be used are: 
EmricasaN for which a clinical trial is ongoing for non-alcoholic steatohepatitis 
fibrosis and IDN-6556 in phase 2 clinical trial for Hepatitis C.  
 
5.1.4 mTORC stimulation  
 
Very recently a novel drug target for RFS has surfaced in a study published by 
Grahammer and co-workers [92]. The deficiency of mTORC1, an important regulator 
of lipid metabolism, was shown in a mouse model, to lead to a renal FS with reduced 
expression of PGC1-alpha, a key regulator of mitochondrial fatty acid oxidation [90]. 
The development of specific drugs targeting mTORC1 continues to grow, mainly for 
specific forms of cancer, including renal cell carcinoma, based on its function as a 
nutrient, redox, oxygen sensor and as an important stimulant for protein synthesis. 
Its activity is up-regulated by the amino acid leucine and its derivative beta hydroxyl 
beta methylbutyrate. The current knowledge supports the hypothesis that the 
stimulation of mTORC1 by amino acids like amino-acid-directed therapies may 
provide a mitochondrial-directed therapeutic approach for RFS [93].  
 
5.1.5. RNA silencing in MODY1 with RFS, FRTS1, FRTS3, and acquired forms 
of RFS 
 
Recently RNA silencing has been successfully used to develop novel management 
strategies, like for instance the use of the FDA-approved mipomersen, an 
apolipoprotein B synthesis inhibitor to lower LDL cholesterol in patients with 
homozygous familial hypercholesterolaemia. RNA silencing shows potential 
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applicability in future clinical trials for the down-regulation of the disease specific 
alleles in dominant genetic diseases, in this way allowing the on-going functionality 
of the wild type allele. So far this has only been demonstrated using disease models 
[94]. This approach could then be used for FRTS1, FRTS3, and MODY1 with renal 
Fanconi syndrome giving the dominant nature of the inheritance. 
 
Recently a novel target for a RNA silencing therapeutic approach in RFS emerged 
as the MicroRNA Mir21. This microRNA appeared to be a novel biomarker for 
proximal tubulopathies underlying AKI [95]. These novel findings, interestingly, point 
towards an important role of Mir21 in regulating metabolic activity in epithelial cells, 
in particular of lipid metabolism [96], as well as apoptosis related genes [95, 97], 
which are important pathways that are affected in several forms of RFS [98]. Mir21 
could therefore be considered as an outstanding candidate to develop novel anti-
sense therapeutics (antagomirs and mimics) for acquired forms of RFS in which 
these pathways are affected: tyrosinemia type I [85], cystinosis [99] and fumaric acid 
ester associated RFS [100]. This could also be the therapeutical target for RFS with 
defective fatty acid oxidation pathways.  
 
5.2. Conclusion 
Unequivocally clinicians and researchers are increasingly aware of the impact of 
RFS. Although the area of the treatment is at the moment the most disappointing, 
new experimental approaches and more testing of novel and existing therapeutic 
agents to will decipher potential model systems for RFS.  
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Moreover, understanding of the impact of mitochondria and its relevance in the area 
of RFS hold much promise for future development of novel therapeutics for this 
complex class of diseases.  
 
Our understanding of the pathogenesis of RFS will continue to improve also by 
unravelling the pathomechanism for the mono-genetic RFS FRTS2, and other 
families, where the causative genetic component has not yet been identified. 
In this manuscript we discussed several potential future options for therapy in 
specific types of RFS. 
• Targeting protein import problems in ATP deficiency related RFS  
• Anti-apoptotic therapy for fumaric acid ester induced RFS, tyrosinemia type I 
and cystinosis 
• RNA silencing in MODY1 with RFS, FRTS1, FRTS3, and acquired forms of 
RFS 
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Table 1: Overview of different types of renal Fanconi syndrome  
Name OMIM  Gene Inheritance Other symptoms 
Cystinosis 
(infantile) 
219800 CTNS AR  Corneal cystine crystals, poor 
growth, rickets, CKD and ESRF 
Fanconi-Bickel 
Syndrome 
227810 GLUT2 
(SLC2A2) 
AR Glycogen storage disease, 
hypoglycemia 
Tyrosinemia Type 1 276700 FAH AR Progressive liver disease, liver 
cancer 
Galactosemia 230400 GALT AR Liver dysfunction, jaundice, 
encephalopathy, sepsis 
Hereditary Fructose 
Intolerance 
229600 ALDOB AR Hypoglycemia, vomiting, liver 
disease 
Wilson Disease 277900 ATP7B AR Liver disease, neurological 
abnormalities, Kayser-Fleischer 
rings 
Lowe Syndrome 309000 OCRL XLR Cataract, mental impairment, 
rickets 
Dent I 300009 CLCN5 XLR Male predominance 
Dent II 300555 OCRL XLR Male predominance 
MODY 1 125850 HNF4A AD Neonatal hyperinsulinism, 
maturity-onset of diabetes in the 
young 
FRTS1 134600 ? AD Chronic kidney disease 
FRTS2 613388 SLC34A1 AR Mainly phosphaturia 
FRTS3 615605 EHHADH AD No chronic kidney disease 
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Figure 1: Schematic of renal proximal tubular cell with key transepithelial transport 
systems. 
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Figure 2: Potential therapeutic solutions linked to restoration of mitochondrial energy 
metabolism in renal Fanconi syndromes. 
 
Drugs could be developed against mTORC1, which has recently been linked to 
causing a renal Fanconi-like syndrome in a mouse model deficient of mTORC1. 
Furthermore DECA-associated therapeutics could be developed for renal Fanconi 
syndromes, in particular for FRTS3, since it is an effective FDA-approved 
mitochondrial targeting agent. Also antisense-Mir21 could be considered an 
important target since Mir-21 is considered a biomarker for AKI, and it has been 
shown to be an effective treatment for restoration of kidney function in Alport 
nephropathy. Other important therapeutic interventions could be fibrates and 
carnitine supplementation for acquired forms of renal Fanconi syndrome. 
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